Stifel Financial Corp Purchases 389,307 Shares of Teligent, Inc. (TLGT)
Stifel Financial Corp increased its position in Teligent, Inc. (NASDAQ:TLGT) by 51.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,141,741 shares of the company’s stock after purchasing an additional 389,307 shares during the period. Stifel Financial Corp owned 2.14% of Teligent worth $7,685,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of the stock. Rhumbline Advisers grew its stake in Teligent by 0.4% in the second quarter. Rhumbline Advisers now owns 49,622 shares of the company’s stock worth $454,000 after purchasing an additional 200 shares during the period. Voya Investment Management LLC boosted its holdings in Teligent by 16.1% in the second quarter. Voya Investment Management LLC now owns 23,342 shares of the company’s stock worth $214,000 after acquiring an additional 3,234 shares in the last quarter. Bank of America Corp DE boosted its holdings in Teligent by 9.1% in the first quarter. Bank of America Corp DE now owns 39,458 shares of the company’s stock worth $307,000 after acquiring an additional 3,293 shares in the last quarter. Teachers Advisors LLC boosted its holdings in Teligent by 7.6% in the second quarter. Teachers Advisors LLC now owns 74,109 shares of the company’s stock worth $678,000 after acquiring an additional 5,216 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its holdings in Teligent by 5.4% in the second quarter. TIAA CREF Investment Management LLC now owns 111,506 shares of the company’s stock worth $1,020,000 after acquiring an additional 5,691 shares in the last quarter. 70.83% of the stock is currently owned by institutional investors.
Several equities research analysts have commented on TLGT shares. Roth Capital set a $9.00 target price on Teligent and gave the stock a “buy” rating in a report on Wednesday, August 23rd. Zacks Investment Research raised Teligent from a “strong sell” rating to a “hold” rating in a report on Friday, October 13th. TheStreet downgraded Teligent from a “c-” rating to a “d+” rating in a report on Wednesday, November 1st. Finally, Canaccord Genuity downgraded Teligent from a “buy” rating to a “hold” rating and dropped their target price for the stock from $9.00 to $5.00 in a report on Tuesday, November 7th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. Teligent currently has a consensus rating of “Hold” and an average price target of $7.00.
Shares of Teligent, Inc. (TLGT) opened at $3.89 on Thursday. The company has a debt-to-equity ratio of 2.23, a current ratio of 3.28 and a quick ratio of 2.71. Teligent, Inc. has a 1-year low of $2.82 and a 1-year high of $9.54.
Teligent (NASDAQ:TLGT) last released its earnings results on Monday, November 6th. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.07). Teligent had a negative return on equity of 6.51% and a negative net margin of 16.95%. The company had revenue of $13.65 million during the quarter, compared to the consensus estimate of $19.12 million. During the same period last year, the firm posted $0.01 earnings per share. The company’s revenue was down 15.5% compared to the same quarter last year. analysts anticipate that Teligent, Inc. will post -0.2 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/12/14/stifel-financial-corp-purchases-389307-shares-of-teligent-inc-tlgt.html.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.